Meta-led selloff drags Nasdaq and S&P 500 below key 50-day levels as investors weigh a choppy earnings and biotech backdrop

U.S. stock index futures pointed lower on Oct. 23 as investors moved into a more cautious posture across equities, with market coverage tying the decline to two different forces: a steep reaction in biotech after Moderna and a technology-led pressure tied to AI-linked names, where Meta was cited as a key driver.

In the same coverage, the S&P 500 and Nasdaq were described as trading below their 50-day moving averages, a widely watched technical benchmark that tracks the average closing price over the prior 50 trading sessions. When major indexes slip beneath that line, traders often interpret it as a sign that near-term momentum has weakened and that investors may demand more confirmation before adding risk.

The broader narrative in the report was that Meta helped fuel an “AI meltdown” selloff, with the tech-heavy Nasdaq taking particular pressure. The report linked Meta’s move to a wider rotation out of AI-linked stocks, a dynamic that has been recurring in periods when investors reassess growth expectations, margins, and spending plans tied to artificial intelligence infrastructure.

Alongside the technology move, the report also highlighted a separate shock in the biotech space, saying Moderna “crashed.” In market terms, that kind of repricing can ripple beyond biotech because it reshapes overall sentiment about earnings durability and the reliability of forward guidance, particularly for sectors that are sensitive to financing conditions and risk appetite.

The story also referenced a “Warren Buffett market” framing, suggesting that investors were still finding pockets of support in more value-oriented or cash-flow centered areas even as high-growth stocks sold off. While the coverage did not specify the exact constituents of that theme, the description reflected a common market behavior: when growth stocks de-rate quickly, some investors look toward more mature business models and steadier earnings profiles.

For Meta, the immediate takeaway from the coverage was not a company-specific announcement, but rather how positioning in AI-related equities translated into trading pressure. Meta is one of the world’s largest providers of consumer social platforms, and it has also been an active participant in the AI arms race. In equity-market terms, however, what matters day-to-day is the market’s marginal view on whether AI spending and product momentum will convert into durable revenue and cost advantages.

Still, the details provided in the market report were limited on specifics. It did not lay out what, exactly, investors were reacting to in Meta’s case (for example, whether it was tied to a particular disclosure, a guidance read-through, or sector-wide expectations). The report also did not offer quantified moves by name, nor did it provide a clear timeline of how the Nasdaq and S&P were trending in relation to the 50-day line intraday.

As the market digests the combination of biotech volatility and AI-stock pressure, traders are likely to focus on follow-through. The most immediate item to watch is whether the indexes can reclaim the 50-day averages and whether the selloff in AI-linked equities stabilizes, or instead broadens into a wider earnings and multiple reset across technology.